Deutsche Bank Aktiengesellschaft Lowers Haleon (LON:HLN) Price Target to GBX 320

Haleon (LON:HLN) had its target price decreased by equities researchers at Deutsche Bank Aktiengesellschaft from GBX 335 to GBX 320 in a research note issued on Wednesday, Digital Look reports. The firm presently has a “sell” rating on the stock. Deutsche Bank Aktiengesellschaft’s price objective points to a potential downside of 4.36% from the company’s previous close.

HLN has been the subject of a number of other reports. JPMorgan Chase & Co. cut their target price on Haleon from GBX 335 to GBX 315 and set an “underweight” rating for the company in a research report on Thursday, June 25th. Royal Bank Of Canada raised their price target on Haleon from GBX 370 to GBX 390 and gave the stock a “sector perform” rating in a research report on Tuesday, August 11th. Berenberg Bank boosted their price target on Haleon from GBX 512 to GBX 514 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 400 price target on shares of Haleon in a research note on Friday, July 31st. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of GBX 396.50.

Haleon Trading Down 0.8%

Shares of HLN stock opened at GBX 334.60 on Wednesday. The company has a current ratio of 0.69, a quick ratio of 0.93 and a debt-to-equity ratio of 50.38. The stock has a market cap of £29.43 billion, a P/E ratio of 18.49, a price-to-earnings-growth ratio of 1.49 and a beta of 0.24. The stock has a 50 day simple moving average of GBX 363.41 and a 200 day simple moving average of GBX 358.63. Haleon has a 1 year low of GBX 317.80 and a 1 year high of GBX 416.10.

Haleon (LON:HLN) last issued its quarterly earnings results on Thursday, July 30th. The company reported GBX 8.60 earnings per share (EPS) for the quarter. Haleon had a return on equity of 9.89% and a net margin of 14.55%. On average, research analysts predict that Haleon will post 19.5033282 earnings per share for the current fiscal year.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.